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Abstract Adiponectin is an adipose tissue speciWc pro-
tein that is decreased in subjects with obesity and type 2
diabetes. The objective of the present study was to examine
whether variants in the regulatory regions of the adipo-
nectin gene contribute to type 2 diabetes in Asian Indians.
The study comprised of 2,000 normal glucose tolerant (NGT)
and 2,000 type 2 diabetic, unrelated subjects randomly
selected from the Chennai Urban Rural Epidemiology
Study (CURES), in southern India. Fasting serum adipo-
nectin levels were measured by radioimmunoassay. We
identiWed two proximal promoter SNPs (¡11377C!G and
¡11282T!C), one intronic SNP (+10211T!G) and one
exonic SNP (+45T!G) by SSCP and direct sequencing in
a pilot study (n = 500). The +10211T!G SNP alone was
genotyped using PCR-RFLP in 4,000 study subjects. Logis-
tic regression analysis revealed that subjects with TG geno-
type of +10211T!G had signiWcantly higher risk for
diabetes compared to TT genotype [Odds ratio 1.28; 95%
ConWdence Interval (CI) 1.07–1.54; P = 0.008]. However,
no association with diabetes was observed with GG geno-
type (P = 0.22). StratiWcation of the study subjects based on
BMI showed that the odds ratio for obesity for the TG
genotype was 1.53 (95%CI 1.3–1.8; P < 10¡7) and that for
GG genotype, 2.10 (95% CI 1.3–3.3; P = 0.002). Among
NGT subjects, the mean serum adiponectin levels were
signiWcantly lower among the GG (P = 0.007) and TG
(P = 0.001) genotypes compared to TT genotype. Among
Asian Indians there is an association of +10211T!G poly-
morphism in the Wrst intron of the adiponectin gene with
type 2 diabetes, obesity and hypoadiponectinemia.
Introduction
Adiponectin, encoded by the ADIPOQ gene, is one of the
adipocyte-expressed proteins that enhances insulin sensi-
tivity and functions in regulating the homeostatic control of
glucose, lipid and energy metabolism (Hu et al. 1996; Diez
et al. 2003). Recent genome wide scans have mapped a sus-
ceptibility locus for type 2 diabetes and obesity/metabolic
syndrome to chromosome 3q27, where the ADIPOQ gene
is located (Kissebah et al. 2000; Vionnet et al. 2000;
Comuzzie et al. 2001; Lindsay et al 2003). Single nucleo-
tide polymorphisms (SNPs) of ADIPOQ gene have been
genotyped in large datasets from various ethnic groups and
several SNPs associated with hypoadiponectinemia, obesity
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600 Hum Genet (2008) 123:599–605and type 2 diabetes have been identiWed (Menzaghi et al.
2002; Vasseur et al. 2003; Gibson et al. 2004; Berthier
et al. 2005; Heid et al. 2006).
Asian Indians are known to have increased susceptibility
to diabetes compared to Europeans (McKeigue et al. 1992).
It has been shown that for any given body mass index
(BMI), Asian Indians have higher body fat (particularly vis-
ceral adiposity), higher plasma insulin levels and greater
insulin resistance compared to Europeans (Mohan et al.
1986; Sharp et al. 1987). They have also been reported to
have lower adiponectin levels (Abate et al. 2004). It is pos-
sible that some of the metabolic abnormalities can be
explained by genetic factors. In this context, the adipo-
nectin gene, which has been associated with important
metabolic eVects in several populations (Weyer et al. 2001;
Mohan et al. 2005) is of great interest. The aim of our study
was to examine whether the variants in the regulatory
regions of the adiponectin gene contribute to the metabolic
abnormalities of type 2 diabetes in Asian Indians. For this,
we screened the entire promoter, the Wrst intron (a region
where SNPs have been previously associated with type 2
diabetes) and the coding regions of the adiponectin gene for
novel variations and evaluated the association of the identi-
Wed variants with type 2 diabetes, obesity and serum adipo-
nectin levels.
Materials and methods
Subjects
A total of 4,000 unrelated study subjects (1,762 men and
2,238 women; mean age 46 § 13 years; mean BMI
24.3 § 4.7 kg/m2) were recruited from the Chennai Urban
Rural Epidemiology Study (CURES), an ongoing epidemio-
logical study conducted on a representative population of
Chennai, the fourth largest city in India with a population
of about 4.2 million. The methodology of the study is pub-
lished elsewhere (Deepa et al. 2003) and is brieXy outlined
here. In Phase I of CURES, 26,001 individuals were
recruited based on a systematic random sampling tech-
nique. Self reported diabetic subjects on drug treatment of
diabetes were classiWed as ‘known diabetic subjects’. Fast-
ing capillary blood glucose was determined using a One
Touch Basic glucometer (Lifescan, Johnson & Johnson,
Milpitas, CA, USA) in all subjects. In Phase 2, all the
known diabetic subjects (n = 1,529) were invited to the
centre for detailed studies on vascular complications. In
addition, all subjects with fasting blood glucose levels in
the diabetic range based on ADA fasting criteria (The
Expert Committee Report 1997), underwent oral glucose
tolerance tests (OGTT) using 75 gm oral glucose load (dis-
solved in 250 ml of water). Those who were conWrmed by
OGTT to have 2 h plasma glucose value ¸11.1 mmol/L
(200 mg/dl) based on WHO consulting group criteria
(Alberti et al. 1998) were labeled as ‘newly detected dia-
betic subjects’. Subjects who had fasting plasma glucose
<110 mg/dL and 2-h plasma glucose value of <140 mg/dL
were categorized as normal glucose tolerant (NGT)
subjects.
Anthropometric measurements including weight, height
and waist circumference were measured using standard
methods. The body mass index (BMI) was calculated using
the formula, weight (kg)/height (m2) and obesity was clas-
siWed as BMI ¸ 25 according to WHO Asia PaciWc Guide-
lines for Asians (The Asia PaciWc perspective 2000).
Fasting plasma glucose (glucose oxidase–peroxidase
method), serum cholesterol (cholesterol oxidase–peroxi-
dase–amidopyrine method), serum triglycerides (glycerol
phosphate oxidase–peroxidase–amidopyrine method) and
HDL cholesterol (direct method-polyethylene glycol-pre-
treated enzymes) were measured using Hitachi-912 Auto-
analyser (Hitachi, Mannheim, Germany).
Total serum adiponectin was measured by radioimmuno-
assay (cat.no. HADP-61 HK;Linco research , St. Charles,
MO, USA ) in a subset of study subjects (n = 911) chosen
randomly using computer generated random numbers. The
intra- and inter-assay coeYcients of variation were 0.38
and 0.74, respectively, and the lower detection limit was
1 ng/mL.
The study subjects comprised 2,000 patients with type 2
diabetes (919 men and 1,081 women) and 2,000 normal
glucose tolerant subjects (843 men and 1,157 women).
Written informed consent was obtained from all subjects
before enrollment in the study. This study was approved by
the Madras Diabetes Research Foundation Ethical Com-
mitee (Institutional Review Board).
Genetic analysis
As a pilot screening, the promoter, the Wrst intron and the
entire coding regions of the adiponectin gene were screened
for variations in the ADIPOQ gene using PCR-SSCP and
sequencing on ABI 310 automated sequencer in 500 sub-
jects (250 NGT and 250 type 2 diabetic subjects). SSCP
technique was used to screen for SNPs using D Code Uni-
versal Mutation Detection System (Biorad, USA). PCR was
performed using radioactive -P33. Electrophoresis was
carried out using 8% acrylamide gel, at room temperature
(approximately 25°). The gel was run for 2 h at 100 V, 1 h
at 150 V and 5 h at 200 V. The gel was transferred to
Whatman paper and kept for exposure in a phosphorim-
ager cassette for 12 h and blot was developed in the
Phosphorimager facility. SNP +10211T!G was genotyped
in a large number by Wrst amplifying a PCR fragment of
228 bp using the forward: 5-GCTAAGTATTACAGATTT123
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GAGC-3 primers and then digesting with HinfI restriction
enzyme (MBI Fermentos, Maryland, USA). The assays
were performed by a technician who was blinded to the
phenotype. To assure that the genotyping was of adequate
quality, we performed random duplicates in 20% of the
samples and found 98% concordance in genotyping.
Statistical analysis
Statistical Package for Social Sciences (SPSS) Windows,
version 10.0, was used for statistical analysis. The eVects of
the polymorphisms on quantitative and categorical vari-
ables were analyzed. Chi-square test was used to compare
the proportions of genotypes or alleles. The genotypic fre-
quencies in both cases and controls showed no signiWcant
departure from the HWE (P > 0.05). One-way ANOVA
was used to compare groups for continuous variables.
Logistic regression analysis (simple logistic model) was
used to identify the risk of the genotypes for type 2 diabetes
and obesity. Type 2 diabetes or obesity was taken as the
dependent variable and the genotypes as the independent
variable; both additive and dominant models were
explored. For additive model, using TT as reference, odds
ratio for TG and GG were computed. For dominant model,
both TG and GG were combined together as XG
(TG + GG) and compared against TT as reference. As sub-
jects with diabetes were older and had higher BMI, we
adjusted for age, sex and BMI in all the logistic regression
analysis. It is possible that some of our controls which are
younger in age will develop diabetes since the prevalence
of diabetes increases with age. In order to circumvent this
problem age was adjusted for in the logistic analysis.
Further to adjust for the possible confounding eVect of
age, sex and BMI, these were included as covariates in the
analysis of type 2 diabetes. For analyzing the risk of obes-
ity, age, sex and type 2 diabetes were included as covari-
ates. Adiponectin values were log transformed to obtain a
normal distribution. P < 0.05 was considered statistically
signiWcant. Bonferroni correction (adjusting for four tests)
for testing multiple phenotypes was carried out.
Results
The type 2 diabetic subjects were older (51 § 11 years)
compared to the NGT subjects (39 § 12 years; P < 0.0001)
and also had higher BMI (P < 0.0001 ) and waist circum-
ference (P < 0.0001). Total cholesterol (P < 0.0001), serum
triglycerides (P < 0.0001), systolic and diastolic blood
pressure (P < 0.0001) were also signiWcantly higher in the
type 2 diabetic subjects (Table 1).
We identiWed two proximal promoter SNPs,
¡11377C!G (rs266729) and ¡11282T!C (rs266732),
one intronic SNP, +10211T!G (rs17846866), and one
exonic SNP, +45T!G (rs2241766), by SSCP and direct
sequencing in the pilot screening (Fig. 1). Among the four
variants studied, the +10211T!G alone was signiWcantly
associated with type 2 diabetes in the pilot study and hence,
this SNP alone was genotyped on a larger population of
4,000 subjects, comprising of 2,000 type 2 diabetic subjects
(919 men and 1,081 women) and 2,000 NGT subjects (843
men and 1,157 women).
Table 2 shows that the frequency of the TG genotype of
+10211T!G SNP was signiWcantly higher in type 2 dia-
betic patients (21.4%) than the NGT subjects (16.6%;
TTvsTG; P = 0.000308). The frequency of the GG geno-
type of +10211T!G SNP was also higher among type 2
diabetic patients (2.0%) compared to NGT subjects (1.2%).
The diVerence was marginally signiWcant (P = 0.046) but
Table 1 Clinical and biochemi-
cal characteristics of the study 
population (CURES)
Characteristics Normal glucose tolerant 
(NGT) subjects (n = 2000)
Type 2 diabetes 
subjects (n = 2000) 
P value
Gender (men/ women) 843/1157 919/1081
Age (years) 39 § 12 51 § 11 <0.0001
Body mass index (BMI) (kg/m2) 23.4 § 4.7 25.3 § 4.3 <0.0001
Waist (cm) 83.5 § 12.1 90.5 § 10.1 <0.0001
Systolic blood pressure (mmHg) 117.3 § 17.0 129.4 § 20.4 <0.0001
Diastolic blood pressure (mmHg) 73.8 § 11.1 77.8 § 11.3 <0.0001
Fasting plasma glucose (mg/dL) 85.5 § 9.3 162.2 § 71.2 <0.0001
HbA1c (%) 5.6 § 0.5 8.7 § 2.3 <0.0001
Fasting serum insulin (IU/mL) 8.4 § 5.8 11.3 § 7.4 <0.0001
Serum cholesterol (mg/dL) 177.4 § 37.6 198.6 § 42.8 <0.0001
Serum triglycerides (mg/dL) 115.0 § 67.4 177.1 § 127.0 <0.0001
HDL cholesterol (mg/dL) 43.6 § 9.9 42.3 § 9.4 <0.0001
LDL cholesterol (mg/dL) 110.9 § 31.9 120.9 § 38.5 <0.0001Data shown in the table are 
mean § SD123
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The frequency of the ‘G’ allele was signiWcantly higher in
type 2 diabetic subjects (0.13) compared to NGT subjects
(0.10; P = 0.000009).
Logistic regression analysis revealed that subjects with
TG genotype of the SNP had signiWcantly higher risk for
diabetes compared to TT genotype [Odds ratio 1.28; 95%
ConWdence Interval (CI) 1.07–1.54; P = 0.008]. However,
there was no association of the GG genotype with diabetes
(Odds ratio 1.38; 95% CI 0.83–2.29; P = 0.22) (Table 2).
The lack of association with the GG genotype may be due
to low frequencies of that genotype in both the type 2 dia-
betes and NGT groups. We accordingly performed a logis-
tic regression analysis under an additive model by coding
the genotypes as 0, 1 and 2. The regression showed that the
odds ratios for TT vs. GG and TG vs. GG were not statisti-
cally signiWcant (Table 2). Thus, it is unlikely that an addi-
tive model of inheritance can explain the eVect of the SNP
in modulating the risk for type 2 diabetes. This raised the
possibility of a dominant mode of inheritance since one
copy of the G allele (TG) conferred signiWcantly higher risk
compared to TT while two copies of the allele (GG) did not
have higher risk than one copy. When the TG and GG
genotypes were combined as XG, it was signiWcantly diVer-
ent compared to the TT genotype with an adjusted odds
ratio of 1.28 (95% CI 1.07–1.53; P = 0.006) with a signiW-
cant genotypic diVerence between the two groups
(P = 0.000068) (Table 2). This is consistent with a domi-
nant model.
The NGT subjects with GG (27.8 § 4.4 kg/m2;
P < 10¡7) and TG (23.9 § 4.7 kg/m2; P = 0.018) genotypes
of +10211T!G had signiWcantly higher BMI compared to
TT (23.2 § 4.6 kg/m2). Therefore, in order to analyze the
possible association of the +10211T!G SNP with obesity,
the study subjects were stratiWed based on BMI as non-
obese (<25 kg/m2) and obese (¸25 kg/m2). The minor
Fig. 1 Adiponectin gene 
showing the location of the 
SNPs identiWed in the present 
study
Table 2 Association of +10211 T!G intronic polymorphism of adiponectin (ADIPOQ) gene with type 2 diabetes and obesity
OR odds ratio, MAF minor allele frequency
* P values showing signiWcance (<0.05) were corrected for multiple comparisons
Association of the +10211 T!G of ADIPOQ gene with type 2 diabetes
Genotypes NGT subjects 
(n = 2000)
Type 2 diabetes 
subjects (n = 2000)
P value* OR (95% CI); P value 
(adjusted for age, sex and BMI)
TT 1643 (82.2%) 1532 (76.6%) 0.000308 (TT vs. TG) 1.28 (1.07 – 1.54), 0.008 (TT vs. TG)
TG 332 (16.6%) 428 (21.4%) 0.493 (TG vs. GG) 0.91 (0.53 –1.55), 0.72 (TG vs. GG)
GG 25 (1.2%) 40 (2.0%) 0.18, (TT vs. GG) 1.38 (0.83 – 2.29), 0.22 (TT vs. GG)
XG (TG + GG) 357 (17.8%) 468 (23.4%) 0.000068 (TT vs. XG) 1.28 (1.07 – 1.53), 0.006 (TT vs. XG)
MAF (G allele) 0.10 0.13 0.000009 –
Association of the +10211 T!G of ADIPOQ gene with obesity
Genotypes Non-obese subjects 
(n = 2335)
Obese subjects 
(n = 1665)
P value* OR (95% CI), P value 
(adjusted for age, sex and diabetes)
TT 1934 (82.8%) 1241 (74.5%) < 10¡7 (TT vs. TG) 1.53 (1.3 – 1.8), < 10¡7 (TT vs. TG)
TG 376 (16.1%) 384 (23.1%) 0.115 (TG vs. GG) 1.40 (0.87 – 2.26), 0.161 (TG vs. GG)
GG 25 (1.1%) 40 (2.4%) 0.0016 (TT vs. GG) 2.10 (1.3– 3.3 ), 0.002 (TT vs. GG)
XG (TG + GG) 401 (17.2%) 424 (25.5%) <10¡7 (TT vs. XG) 1.57 (1.34 – 1.84), <10¡7 (TT vs. XG) 
MAF (G allele) 0.09 0.14 <10¡7 -123
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(0.14) compared to non-obese subjects (0.09; P < 10¡7).
The frequency of the TG genotype of +10211T!G SNP
was signiWcantly higher in obese subjects (23.1%) com-
pared to non-obese subjects (16.1%; P < 10¡7). Also, the
frequency of the GG genotype was signiWcantly higher
among obese subjects (2.4%) compared to non-obese sub-
jects (1.1%; P = 0.0016) after correcting for multiple test-
ing (Table 2). However, when the GG genotype was
compared to TG genotype there was no signiWcance
(P = 0.115). Logistic regression analysis revealed the odds
ratio (adjusted for age, sex and type 2 diabetes) for obesity
for the individuals carrying the TG genotype to be 1.53
(95% CI 1.3–1.8; P < 10¡7), while for those carrying GG
genotype it was 2.10 (95% CI 1.3–3.3; P = 0.002). How-
ever, a comparison of TG versus GG showed no signiW-
cance (Table 2). We compared the TT versus XG (1.57;
95% CI 1.35–1.84; P < 10¡7) and found statistical signiW-
cance. Hence, the association of this genotype with obesity
is also consistent with a dominant model.
Based on the pilot screening, linkage disequilibrium
(LD) was computed among the four SNPs and it was found
that the r2 values are consistent in the two groups and did
not provide evidence of pairwise LD between the SNPs
(Table 3).
Linear regression analysis using BMI as the dependent
variable and genotypes as independent variable revealed
the -coeYcient to be 0.14 which was highly signiWcant
(P < 0.0001).
As the SNP showed association with both diabetes and
obesity, we further investigated its possible association
with serum adiponectin levels. The mean serum adiponec-
tin levels were measured in 911 randomly selected subjects
(408 NGT and 503 type 2 diabetic subjects) and the results
were analyzed using a mixed eVects model with BMI as a
covariate, along with age and diabetic status as a factor.
The mean serum adiponectin levels were found to be lower
in carriers of the TG and GG genotype compared to the TT
genotype.
Among NGT subjects, the mean serum adiponectin lev-
els (adjusted for age, sex and BMI) were signiWcantly lower
in subjects with GG (4.99 g/mL; 95% CI 3.78–6.56;
P = 0.007) and TG (6.00 g/mL; 95% CI 5.54–6.50;
P = 0.001) compared to TT (7.31 g/mL; 95% CI 6.80–
7.84). Similar results were observed in diabetic subjects
(adjusted for age, sex and BMI) (GG 4.54 g/mL; 95%CI
3.81–5.4; P = 0.017; TG 4.75 g/mL; 95%CI 4.40–5.11;
P < 10¡5; TT 6.03 g/mL; 95% CI 5.61–6.46) (Fig. 2).
Discussion
The novel Wnding of our study is that the subjects carrying
the +10211T!G polymorphism in the Wrst intron of the
adiponectin gene are at a higher risk of type 2 diabetes,
obesity and hypoadiponectinemia in this Asian Indian
population. As this is the Wrst association study of this poly-
morphism, we are unable to compare the genotypic and
allelic frequencies of this SNP with other populations.
Though the study was hypothesized to address the asso-
ciation of diabetes with +10211T!G polymorphism,
secondary analyses revealed this polymorphism to be
associated with obesity and serum adiponectin levels. With
diabetes and obesity the mode of inheritance was dominant.
Given that type 2 diabetes and obesity are highly corre-
Table 3 Pair-wise linkage disequilibrium (LD) values of the four loci
studied
S. No L1 L2 r2 (NGT) r2 (DM)
1 T 10211 G T 45 G 0.009 0.005
2 T 10211 G C 11377 G 0.002 0
3 T 10211 G T 11285 C 0 00.1
4 T 45 G C 11377 G 0.002 0
5 T 45 G T 11285 C 0.001 0.029
6 C 11377 G T 11285 C 0 0.002
Fig. 2 Serum adiponectin values in subjects with TT, TG and GG genotypes of +10211T!G polymorphism
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p= 0.001
p= 0.007
p = 0.000001
p= 0.017
Log transformed adiponectin adjusted for age, sex and BMI 
Data presented as mean and 95% confidence interval(CI)
(n= 221) (n= 163) (n= 24) (n= 239) (n= 230) (n= 34)123
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to both the traits.
Recently it was shown (Qiao et al. 2005) that the DNA
encoding the Wrst intron of the ADIPOQ gene containing
adipocyte-speciWc regulatory elements highly sensitive to
the adipogenic transcription factor C/EBP, confers signiWcant
activity on the ADIPOQ promoter. This intron was shown
to contain a 34-bp enhancer, which regulates adiponectin
gene expression in an adipose tissue speciWc manner. Our
Wnding of the polymorphism close to the enhancer in the
region of the Wrst intron is, therefore, of great signiWcance.
Further studies on the expression levels of adiponectin
could clarify whether the SNP +10211T!G alters the
binding site and also will help understanding the functional
signiWcance of this polymorphism in relation to the lower
serum adiponectin levels observed in this study.
In this study, the +45T!G SNP failed to show an asso-
ciation with type 2 diabetes and obesity, which is similar to
an earlier report in a French Caucasian population (Gibson
et al. 2004). SNP -11377C!G was also not associated with
type 2 diabetes, which is in contrast to the study in a Swed-
ish Caucasian population (Gu et al. 2004). The novel vari-
ant ¡11282 was present in less than 1% in the population
and was seen only in the non-obese subjects.
The LD was computed among the four SNPs and it was
found that the r2 values are consistent in the two groups and
did not provide evidence of pairwise LD between the SNPs
(Table 2). The absence of LD possibly explains why the
+10211 was associated with type 2 diabetes and obesity
while the other SNPs were not. The adiponectin gene
haplotype blocks have been extensively studied in healthy
Caucasians (Gibson et al. 2004). However, additional SNPs
need to be analyzed in order to understand the LD structure
in our population.
The adiponectin gene is known to be very polymorphic:
many exonic, intronic and promoter SNPs have been
reported and this has been recently reviewed (Vasseur et al.
2006). Associations with adiponectin levels and phenotypes
associated with the metabolic syndrome have been reported
for three groups of genetic variants in numerous popula-
tions: in the 5 sequences (¡11282, ¡11426, ¡11391 and
¡11377); in the exon 2 and intron 2 regions (+45 and
+276); and in exon 3 (mostly missense mutations G84R,
G90S, Y11H, R112 C and 1164 T) (Pratley et al. 1998;
Waki et al. 2003; Gibson et al. 2004; Gu et al. 2004; Pollin
et al. 2005). The promoter, intronic and synonymous
exonic SNPs of the ADIPOQ gene are thought to modulate
expression of the gene (or are in linkage disequilibrium
with functional variants that modulate expression of the
gene) whereas missense mutations may not only modulate
adiponectin secretion but also its activity. Therefore, our
Wnding of the intronic SNP +10211T!G showing associa-
tion with adiponectin levels strengthens this hypothesis.
Further, the contribution of adiponectin SNPs to
hypoadiponectinaemia, decreased insulin sensitivity and
type 2 diabetes has been conWrmed in several populations,
although the SNPs involved and populations investigated
vary in diVerent studies (Woo et al. 2006; Hotta et al. 2001;
Daimon et al. 2003). Most studies also agree that variations
at the ADIPOQ locus modulate the genetic risk for type 2
diabetes and other components of the metabolic syndrome
through their eVects on both adiponectin secretion and
activity. It is in this context, that our Wndings gain impor-
tance as they add to the repertoire of SNPs that likely
contribute to the genetic risk of diabetes and obesity.
To address the issue of population stratiWcation, Devlin
et al. (2001) suggested the use of genomic control markers
to estimate the inXation of the false positive rate. We per-
formed a limited genomic control analysis based on six
neutral markers not related to type 2 diabetes and obesity
earlier reported from our country (Roychoudhury et al.
2001). The allele frequency diVerence between cases and
control subjects (classiWed based on diabetic status and
BMI) was not statistically signiWcant at any of the six loci
indicating that the Wndings in this study are not an artefact
of population sub-structuring.
In summary, the present study shows for the Wrst time,
that the +10211T!G polymorphism in the Wrst intron of
the adiponectin gene is associated with type 2 diabetes,
obesity and hypoadiponectinemia in this Asian Indian
population. Further studies are needed to determine the
functional signiWcance of these Wndings and to replicate
these Wndings in other populations.
Acknowledgments The study was supported by a grant from the
Department of Biotechnology (DBT) and Department of Science and
Technology (DST), New Delhi, India. We also thank the Indian Coun-
cil of Medical Research (ICMR). We thank the Chennai Wellingdon
Corporate Foundation for their support for the CURES Weld studies.
This is publication no 60 from CURES (CURES-60).
References
Abate N, Chandalia M, Snell PG, Grundy SM (2004) Adipose tissue
metabolites and insulin resistance in non-diabetic Asian Indian
men. J Clin Endocrinol Metab 89:2750–2755
Alberti KG, Zimmet PZ (1998) DeWnition, diagnosis and classiWcation
of diabetes mellitus and its complications. Part 1: diagnosis and
classiWcation of diabetes mellitus, provisional report of a WHO
consultation. Diabet Med 15:539–553
Berthier MT, Houde A, Cote M, Paradis AM, Mauriege P, Bergeron J,
Gaudet D, Despres JP, Vohl MC (2005) Impact of adiponectin
gene polymorphisms on plasma lipoprotein and adiponectin con-
centrations of viscerally obese men. J Lipid Res 46:237–244
Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ,
Black AE, Maas D, Takahashi M, Kihara S, Tanaka S, Matsuzawa
Y, Blangero J, Cohen D, Kissebah A (2001) The genetic basis of
plasma variation in adiponectin, a global endophenotype for obes-
ity and the etabolic syndrome. J Clin Endocrinol Metab 86:4321–
4325123
Hum Genet (2008) 123:599–605 605Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H
(2003) Decreased serum levels of adiponectin are a risk factor for
the progression to type 2 diabetes in the Japanese Population: the
Funagata study. Diabetes Care 26:2015–2020
Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S,
Mohan V (2003) The Chennai Urban Rural Epidemiology Study
(CURES) study design and methodology (urban component)
(CURES-1). J Assoc Physicians India 51:863–870
Devlin B, Roeder K, Wasserman L (2001) Genomic control, a new ap-
proach to genetic-based association studies. Theor Popul Biol
60:155–166
Diez JJ, Iglesias PB (2003) The role of the novel adipocyte-derived
hormone adiponectin in human disease. Eur J Endocrinol
148:293–300
Gibson F, Froguel P (2004) Genetics of the ADIPOQ locus and its con-
tribution to Type 2 diabetes susceptibility in French Caucasians.
Diabetes 53:2977–2983
Gu HF, Abulaiti A, Ostenson CG, Humphreys K, Wahlestedt C, Broo-
kes AJ, Efendic S (2004) Single nucleotide polymorphisms in the
proximal promoter region of the adiponectin (ADIPOQ) gene are
associated with Type 2 diabetes in Swedish Caucasians. Diabetes
53:S31–S35
Heid IM, Wagner SA, Gohlke H, Iglseder B, Mueller JC, Cip P, Ladur-
ner G, Reiter R, Stadlmayr A, Mackevics V,Illig T,Kronenberg F,
Paulweber B (2006) Genetic architecture of the APM1 gene and
its inXuence on adiponectin plasma levels and parameters of the
metabolic syndrome in 1,727 healthy Caucasians. Diabetes
55:375–384
Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC
(2001) Circulating concentrations of the adipocyte protein adipo-
nectin are decreased in parallel with reduced insulin sensitivity
during the progression to type 2 diabetes in rhesus monkeys. Dia-
betes 50:1126–1133
Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-spe-
ciWc gene dysregulated in obesity. J Biol Chem 271:10697–10703
Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K,
James RG, Marks JA, Krakower RG, Jacob HW, Weber J, Martin
L, Blangero J, Comuzzie AG (2000) Quantitative trait loci on
chromosomes 3 and 17 inXuence phenotypes of the metabolic
syndrome. Proc Natl Acad Sci USA 97:14478–14483
Lindsay RS, Funahashi T, KrakoV J, Matsuzawa Y, Tanaka S, Kobes
S, Bennett PH, Tataranni PA, Knowler WC, Hanson RL (2003)
Genome-wide linkage analysis of serum adiponectin in the Pima
Indian population. Diabetes 52:2419–2425
McKeigue PM, Pierpoint T, Ferrie JE, Marmot MG (1992) Relation-
ship of glucose intolerance and hyperinsulinaemia to body fat pat-
tern in South Asians and Europeans. Diabetologia 35:785–791
Menzaghi C, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer
PE, Trischitta V, Doria A (2002) A haplotype at the adiponectin
locus is associated with obesity and other features of the insulin
resistance syndrome. Diabetes 51:2306–2312
Mohan V, Sharp PS, Cloke HR, Burrin JM, Schumer B, Kohner EM
(1986) Serum immunoreactive insulin responses to a glucose load
in Asian Indian and European type 2 (non-insulin-dependent)
diabetic patients and control subjects. Diabetologia 29:235–237
Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A,
Velmurugan K, Radha V (2005) Association of low adiponectin
levels with the metabolic syndrome—the Chennai Urban Rural
Epidemiology Study (CURES-4). Metabolism 54:476–481
Pollin TI, Tanner K, O’Connell JR, Ott SH, Damcott CM, Shuldiner
AR, McLenithan JC, Mitchell BD (2005) Linkage of plasma
adiponectin levels to 3q27 explained by association with variation
in the APM1 gene. Diabetes 54:268–274
Pratley RE, Thompson DB, Prochazka M, Baier L, Mott D, Ravussin
E, Sakul H, Ehm MG, Burns DK, Foroud T, Garvey WT, Hanson
RL, Knowler WC, Bennett PH, Bogardus C (1998) An autosomal
genomic scan for loci linked to prediabetic phenotypes in Pima
Indians. J Clin Invest 101:1757–1764
Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti
M, Friedman JE, Shao J (2005) C/EBP regulates human adipo-
nectin gene transcription through an intronic enhancer. Diabetes
54:1744–1754
Roychoudhury S, Roy S, Basu A, Banerjee R, Vishwanathan H, Usha
Rani MV, Sil SK, Mitra M, Majumder PP (2001) Genomic struc-
tures and population histories of linguistically distinct tribal
groups of India. Hum Genet 109(3):339–350
Sharp PS, Mohan V, Levy JC, Mather HM, Kohner EM (1987) Insulin
resistance in patients of Asian Indian and European origin with
non-insulin dependent diabetes. Horm Metab Res 19:84–85
The Expert Committee on the Diagnosis and ClassiWcation of Diabetes
(1997) Mellitus report of the Expert Committee on the Diagnosis
and classiWcation of Diabetes Mellitus. Diabetes Care 20:1183–
1197
The Asia PaciWc perspective (2000) RedeWning obesity and its treat-
ment. Regional OYce for the Western PaciWc of the World Health
Organization. World Health Organization, International Associa-
tion for the Study of Obesity and International Obesity Task
Force. Health Communications Australia Pty Limited, pp 22–29
Vasseur F, Lepretre F, Lacquemant C, Froguel P (2003) The genetics
of adiponectin. Curr Diab Rep 3:151–158
Vasseur F,Meyre D, Froguel P (2006) Adiponectin, type 2 diabetes and
metabolic syndrome: lessons from human genetic studies. Expert
Rev Mol Med 8:1–12
Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De
Matos F, Durand E, Leprêtre F, Lecoeur C, Gallina P, Zekiri L,
Dina C, Froguel P (2000) Genomewide search for type 2 diabetes-
susceptibility genes in French Whites: evidence for a novel
susceptibility locus for early-onset diabetes on chromosome
3q27–qter and independent replication of a type 2-diabetes locus
on chromosome 1q21-q24. Am J Hum Genet 67:1470–1480
Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S (2003) Im-
paired multimerization of human adiponectin mutants associated
with diabetes. Molecular structure and multimer formation of
adiponectin. J Biol Chem 278:40352–40363
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE,
Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2
diabetes: close association with insulin resistance and hyperinsu-
linemia. J Clin Endocrinol Metab 86:1930–1935
Woo JG, Dolan LM, Deka R, Kaushal RD, Shen Y, Pal P, Daniels SR,
Martin LJ (2006) Interactions between noncontiguous haplotypes
in the adiponectin gene ACDC are associated with plasma adipo-
nectin. Diabetes 55:523–529123
